Read up on essential news

We want to keep you informed. Here are a few important news items and reminders for you this month.

Changes to our National Precertification List (NPL)

The following new-to-market drugs require precertification*

- Vabysmo® (faricimab) — precertification is required effective May 1, 2022. This drug is part of the ophthalmic medical injectables drugs category.
- Enjaymo™ (Sutimlimab-jome) — precertification for the drug and site of care is required effective May 1, 2022.
- Releuko™ (filgrastim-ayow) — precertification is required effective May 25, 2022. This drug is part of the granulocyte-colony stimulating factor drugs category.
- Carvykti™ (cilcabtagene autoleucel) — precertification is required effective May 27, 2022. This drug is part of the chimeric antigen receptor T-cell (CAR-T) drugs category.

In the April OLU email, we told you about changes to the NPL document. The changes conveyed in the NPL article will now take effect on June 1, 2022.

Submitting precertification requests

Be sure to submit precertification requests at least two weeks in advance. To save time, request precertification online. Doing so is fast, secure and simple.
You can submit most requests online through our Availity provider portal. Or you can use your practice’s Electronic Medical Record (EMR) system if it’s set up for electronic precertification requests. Use our “Search by CPT code” search function on our precertification lists page to find out if the code requires precertification.

Learn more about precertification.

Are you asking for precertification on a specialty drug for a commercial or Medicare member? Then submit your request through Novologix®, also available on Availity.**

Not registered for Availity®? Go to Availity to register and learn more.

*These changes apply to our commercial and Medicare members.
**Availity is available only to U.S. providers and its territories.

Aetna’s annual transition to the new edition of the Milliman Care Guidelines® (MCG)

We use evidence-based clinical guidelines from nationally recognized authorities to make utilization management (UM) decisions. Every year, Aetna® coordinates with MCG to update to their new edition. We use the MCG, among other resources, to make clinical decisions.

As of April 23, 2022, Aetna® updated to the 26th edition of MCG and now uses it for designated reviews regarding both our commercial and Medicare members.

Aetna is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

Help/contact us:
If you have any questions, please contact us.

Want to stop receiving messages like these through email? Unsubscribe at any time.

We are located at 151 Farmington Avenue, Hartford, CT 06156.

Privacy Statement | Terms of Use | Privacy Information

©2022 Aetna Inc.
1074050-01-01